How to Consider Adjunctive Lumateperone for MDD With Anxious Distress
How should clinicians identify patients with major depressive disorder and anxious distress who may be appropriate for adjunctive lumateperone after inadequate antidepressant response?
Patients with major depressive disorder and anxious distress often have poorer outcomes and are less likely to respond to antidepressant therapy alone. This guide applies to adults with an ongoing major depressive episode who remain symptomatic despite antidepressant monotherapy and helps clinicians match real-world patients to the population studied in this post hoc analysis.
-
Confirm persistent major depressive disorder despite antidepressant therapy
Use this approach only in adults with DSM-5 major depressive disorder who are currently experiencing a major depressive episode and have an inadequate response to antidepressant therapy. In the trial, inadequate response meant less than 50% improvement after 1 to 2 antidepressant monotherapies given at at least the minimum effective dose for 6 weeks or longer in the current episode, confirmed with the Antidepressant Treatment Response Questionnaire.
-
Establish that symptom severity is still clinically substantial
The studied population had ongoing moderate to severe depressive symptoms rather than partial residual symptoms alone. Entry criteria included MADRS total score of 24 or higher, CGI-S score of 4 or higher, and QIDS-SR-16 score of 14 or higher at screening and baseline.
-
Assess for DSM-5 anxious distress systematically
Determine whether the current major depressive episode includes anxious distress by checking for 2 or more DSM-5 anxiety symptoms present during most days of the episode. The symptoms used in the study were feeling keyed up or tense, feeling unusually restless, difficulty concentrating due to worry, fear that something awful might happen, and feeling that one might lose control of oneself; the diagnosis was confirmed with the MINI anxious distress module.
-
Check whether the patient resembles the studied population
The findings apply best to adult outpatients aged 18 to 65 years without lifetime schizophrenia, schizoaffective disorder, bipolar disorder, or other psychotic disorders and without significant suicidal risk. Patients with a primary anxiety disorder or anxiety symptoms requiring concurrent treatment were excluded, so the evidence is most applicable when anxiety symptoms are part of major depressive disorder rather than the primary disorder needing separate active treatment.
-
Use lumateperone augmentation when anxious distress strengthens the case for it
In this analysis, adjunctive oral once-daily lumateperone 42 mg added to antidepressant therapy significantly improved depressive symptoms, global severity, and anxiety-related measures versus placebo augmentation in patients with anxious distress. At Day 43, patients with anxious distress had larger effect sizes than those without anxious distress, and the reported NNTs were 3 for MADRS response and 7 for remission, supporting this subgroup as one in whom benefit may be especially meaningful.
-
Set expectations for timing and domains of improvement
For patients with anxious distress, significant MADRS improvement emerged by Day 15 and significant CGI-S improvement by Day 22, with benefits persisting through the 6-week study. Anxiety-related improvement also favored lumateperone in this subgroup, including significant benefit on GAD-7 at Day 43 and on MADRS item 3 inner tension, which the study used as a proxy for anxious distress.
-
Monitor tolerability during augmentation
In lumateperone-treated patients with anxious distress, 62.7% experienced at least 1 treatment-emergent adverse event, 4.5% discontinued because of adverse events, and 9.1% had at least 1 EPS-related treatment-emergent adverse event. Metabolic parameters and prolactin changes were minimal across subgroups in this study.
Clinical Considerations
- This was an exploratory post hoc analysis and the subgroup analyses were not adjusted for multiplicity.
- Patients with a primary anxiety disorder or anxiety symptoms requiring concurrent treatment were excluded, which may limit generalizability to more complex anxiety presentations.
- Benzodiazepines and nonbenzodiazepine anxiolytics were not allowed during the study.
- The evidence comes from adult outpatients aged 18 to 65 years in a 6-week trial, so applicability outside that population or timeframe is uncertain.
Bottom Line
For adults with major depressive disorder who remain symptomatic after an adequate antidepressant trial, DSM-5 anxious distress identifies a subgroup in which adjunctive lumateperone 42 mg had particularly strong 6-week benefits on both depressive and anxiety-related symptoms.
